Oral News and Research

RSS

Herpes virus changes anti-herpes drug acyclovir to form that hinders AIDS virus

The drug acyclovir has long been used to suppress outbreaks of oral and genital herpes. Herpes viruses change acyclovir to a form that prevents them from reproducing.

10 Sep 2008

Bleeding gums increase risk of heart disease

Bad teeth, bleeding gums and poor dental hygiene can cause heart disease, Professor Howard Jenkinson from the University of Bristol will tell members of the Society for General Microbiology in Trinity College, Dublin today [Thursday 11 September].

10 Sep 2008

New drug hope for cystic fibrosis patients

A science conference in the UK has heard some good news which offers hope to cystic fibrosis (CF) patients worldwide.

10 Sep 2008

Pfizer to withdraw global marketing applications for Dalbavancin to conduct a new trial

Pfizer Inc today announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the U.S. new drug application (NDA) and the European marketing authorization application (MAA).

9 Sep 2008

Discovery of new link between gum disease and heart disease

Heart disease is the leading cause of death worldwide. However, many people with cardiovascular disease have none of the common risk factors such as smoking, obesity and high cholesterol. Now, researchers have discovered a new link between gum disease and heart disease that may help find ways to save lives, scientists heard today (Tuesday 9 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.

8 Sep 2008

Seattle department finds OraSure HIV test to be less accurate than label claims

A report by Public Health -- Seattle and King County in Washington state has found that testing with OraSure Technologies' OraQuick test provides less accurate results than the label claims, Bloomberg reports.

7 Sep 2008

Trial demonstrates safety and efficacy of neurally acting anti-migraine agent for treatment of acute migraine

CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches.

7 Sep 2008

Free drug samples may end up costing uninsured more

Free drug samples provided to physicians by pharmaceutical companies could actually be costing uninsured patients more in the long run, according to a study done by researchers at Wake Forest University Baptist Medical Center and colleagues.

7 Sep 2008

Public backs tougher tobacco control to protect the young

More than 8,000 people have written to the Department of Health calling for tougher tobacco control to protect young people and put tobacco out of sight and out of mind.

7 Sep 2008

Heavy snorers at increased risk of stroke

University of Sydney researchers have found that heavy snorers have a higher risk of cholesterol plaque in the neck arteries, leading to an increased risk of stroke.

4 Sep 2008

Sexual activities other than intercourse carry risk of HIV, other STIs, study finds

Sexual activities other than intercourse carry some risk of HIV and other sexually transmitted infections, according to a report from the American College of Obstetricians and Gynecologists published recently in the journal Obstetrics and Gynecology, Reuters reports.

4 Sep 2008

Anadis to commercialise "BioGard" adjunctive therapy for HIV/AIDS

Anadis announced today its commercialization of a new product, BioGard, intended to maintain gastrointestinal and immune system health. The specific formulation may be of particular clinical benefit in persons undergoing antiretroviral therapy for HIV/AIDS.

4 Sep 2008

Vimpat (lacosamide) approved in Europe

UCB announced today that the European Commission (EC) has approved Vimpat (lacosamide) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat is the first new antiepileptic drug (AED) for partial-onset seizures in three years and offers a new treatment option for European patients living with uncontrolled partial-onset epilepsy.

3 Sep 2008

Further analysis from ATHENA study showed Multaq (Dronedarone) reduced risk of stroke in patients with atrial fibrillation

The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany.

3 Sep 2008

Anadis Ltd's clinical trial against mucositis approved in Israel

Anadis Ltd., an Australian biopharmaceutical company specializing in oral immunotherapy using naturally derived antibodies and other proteins is announcing the clinical protocol for its Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski Medical Center's Institutional Review Board (IRB) and by the Israeli Ministry of Health (MOH).

3 Sep 2008

New guidelines for dealing with earwax

Ear Nose and Throat (ENT) specialists in the U.S. have come up with new guidelines for dealing with earwax.

2 Sep 2008

Pre-hospital treatment on the way to percutaneous coronary intervention

For patients with acute ST-segment-elevation AMI (STEMI) within 12 hours after symptom onset and with persistent ST-segment elevation, or new or presumednew left bundle-branch block with concomitant ST-segment elevation, restoring coronary blood flow as early as possible is the main goal of reperfusion strategies.

2 Sep 2008

The effects of A2 inhibitor Darapladib on human coronary athlerosclerotic plaque

A twelve month study of treatment with darapladib concluded that,Lp-PLA2 inhibition with darapladib prevented necrotic core expansion, a key determinant of plaque vulnerability.

2 Sep 2008

Overcoming poor response to standard oral antiplatelet agents

Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.

2 Sep 2008

Earwax removal - new guidelines

The American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) will issue the first comprehensive clinical guidelines to help health care practitioners identify patients with cerumen (commonly referred to as earwax) impaction. The guidelines emphasize evidence-based management of cerumen impaction by clinicians, and inform patients of the purpose of ear wax in hearing health.

1 Sep 2008